Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

American Journal of Kidney Diseases

Volumn 52, Issue 3, 2008, Pages 412-424

  Rahman, Mahboob ^a   Baimbridge, Charles ^b   Davis, Barry R ^b   Barzilay, Joshua ^c   Basile, Jan N ^d   Henriquez, Mario A ^e   Huml, Anne ^a   Kopyt, Nelson ^f   Louis, Gail T ^g   Pressel, Sara L ^b   Rosendorff, Clive ^h,i   Sastrasinh, Sithiporn ⁱ   Stanford, Carol ^j  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e Bronx Nephrology Hypertension   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

^g TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

glomerular filtration rate; Hyperlipidemia; pravastatin

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PRAVASTATIN; TREATMENT OUTCOME;

EID: 49749092687     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.05.027     Document Type: Article

References (37)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 1 (2002) S1-S266
2. Kaysen G.A. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney Int Suppl 104 (2006) S55-S58
3. Manttari M., Tiula E., Alikoski T., and Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26 (1995) 670-675
4. Schaeffner E.S., Kurth T., Curhan G.C., et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14 (2003) 2084-2091
5. Kosch M., Barenbrock M., Suwelack B., Schaefer R.M., Rahn K.H., and Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis 41 (2003) 1088-1096
6. Panichi V., Paoletti S., Mantuano E., et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 21 (2006) 337-344
7. Campese V.M., Nadim M.K., and Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?. J Am Soc Nephrol 16 suppl 1 (2005) S11-S17
8. Bianchi S., Bigazzi R., Caiazza A., and Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565-570
9. Lee T.M., Su S.F., and Tsai C.H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40 (2002) 67-73
10. Thomas M.E., Harris K.P., Ramaswamy C., et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44 (1993) 1124-1129
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
12. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 936-946
13. Levey A.S., Greene T., Kusek J., and Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 0828A (abstr)
14. Grambsch P., and Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrica 81 (1994) 515-526
15. Klein J.P., and Moeschberger M.L. Survival Analysis-Techniques for Censored and Truncated Data. (ed 2) (2003), Springer-Verlag, New York, NY
16. Singer J.D., and Willet J.B. Applied Longitudinal Data Analysis (2003), Oxford University, New York, NY
17. Agarwal R. Effects of statins on renal function. Am J Cardiol 97 (2006) 748-755
18. Atthobari J., Brantsma A.H., Gansevoort R.T., et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21 (2006) 3106-3114
19. Feringa H.H., Karagiannis S.E., Chonchol M., et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 18 (2007) 1872-1879
20. Hommel E., Andersen P., Gall M.A., et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35 (1992) 447-451
21. Nakamura T., Ushiyama C., Hirokawa K., et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17 (2002) 798-802
22. Nielsen S., Schmitz O., Moller N., et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36 (1993) 1079-1086
23. Rayner B.L., Byrne M.J., and van Zyl S.R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46 (1996) 219-224
24. Tonolo G., Ciccarese M., Brizzi P., et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20 (1997) 1891-1895
25. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. J Clin Pathol 57 (2004) 728-734
26. Imai Y., Suzuki H., Saito T., Tsuji I., Abe K., and Saruta T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clin Exp Hypertens 21 (1999) 1345-1355
27. Lam K.S., Cheng I.K., Janus E.D., and Pang R.W. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38 (1995) 604-609
28. Gheith O.A., Sobh M.A., Mohamed K., et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 91 (2002) 612-619
29. Tonelli M., Moye L., Sacks F.M., Cole T., and Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 (2003) 1605-1613
30. Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
31. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
32. Strippoli G.F., Navaneethan S.D., Johnson D.W., et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 336 (2008) 645-651
33. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
34. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
35. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 145 (2006) 117-124
36. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today 11 (2006) 458-464
37. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210